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ABSTRACT
Invasive fungal infection (IFI) is a significant complication after allogeneic hematopoietic stem cell transplan-
tation (HSCT); however, we have little information on its clinical features after reduced intensity cord blood
transplantation (RICBT) for adults. We reviewed medical records of 128 patients who underwent RICBT at
Toranomon Hospital between March 2002 and November 2005. Most of the patients received purine-
analogbased preparative regimens. Graft-versus-host disease (GVHD) prophylaxis was a continuous infusion
of either tacrolimus 0.03 mg/kg or cyclosporine 3 mg/kg. IFI was diagnosed according to the established
EORTC/NIH-MSG criteria. IFI was diagnosed in 14 patients. Thirteen of the 14 had probable invasive
pulmonary aspergillosis and the other had fungemia resulting from Trichosporon spp. Median onset of IFI was
day 20 (range: 1-82), and no patients developed IFI after day 100. Three-year cumulative incidence of IA was
10.2%. Four of the 13 patients with invasive aspergillosis (IA) developed grade II-IV acute GVHD, and their
IA was diagnosed before the onset of acute GVHD. The mortality rate of IFI was 86%. Multivariate analysis
revealed that the use of prednisolone >0.2 mg/kg (relative risk 7.97, 95% confidence interval 2.24-28.4, P 
.0014) was a significant risk factor for IA. This study suggests that IFI is an important cause of deaths after
RICBT, and effective strategies are warranted to prevent IFI.
© 2007 American Society for Blood and Marrow Transplantation
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iNTRODUCTION
Cord blood transplantation (CBT) is an attractive
lternative for patients with hematologic diseases who
ack a matched related or unrelated donor. The useful-
ess of CBT using myeloablative preparative regimens
as been conﬁrmed for pediatric patients [1,2]. Myeloa-
lative CBT for adult patients achieves engraftment in
0% of the patients, but carries 50% risk of transplant-
elated mortality (TRM), mostly resulting from infection
3,4]. We and other groups have reported the feasibility of
BT using reduced-intensity regimens (RICBT) for adult
atients with advanced hematologic diseases [5,6]. wBecause of delayed immune recovery and graft-ver-
us-host disease (GVHD), infection is the leading cause
f TRM after CBT using myeloablative preparative reg-
mens [2-4,7]. However, studies on immune recovery
ollowing RICBT gave us hope that RICBT recipients
ay less frequently experience GVHD and infectious
omplications. Invasive fungal infection (IFI) has been 1
f the most feared infectious complications in conven-
ional allogeneic marrow or peripheral blood stem cell
PBSC) transplantation [8,9], whereas we have little in-
ormation on IFI following RICBT. We investigated its
ncidence and clinical features in patients who under-
ent RICBT for advanced hematologic diseases.
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S. Miyakoshi et al.772ATIENTS AND METHODS
ata Collection
We reviewed medical records of 128 recipients
ho underwent ﬁrst reduced-intensity allogeneic he-
atopoietic stem cell transplantation (HSCT) using
ord blood (CB) between March 2002 and November
005 at Toranomon Hospital. Their characteristics
re shown in Table 1. Of the 128 patients, 101 had
igh-risk diseases including acute myelogenous leukemia
AML) in relapse or the second and higher complete
emission (CR; n  42), acute lymphoid leukemia
ALL) except those in the ﬁrst CR (n  12), chronic
yelogenous leukemia (CML) in blastic phase (n 4),
able 1. Patients’ Characteristics and Transplantation Procedures
Variables Number
atients Characteristics
Age, median (range) 56 (17-71)
Sex, male/female 80/48
Primary diseases
AML/MDS 63
Malignant lymphoma 33
Acute lymphoblastic leukemia 17
Severe aplastic anemia 6
Chronic myelogenous leukemia 6
Chronic myelomonocytic leukemia 1
Plasmacytic leukemia 1
Idiopathic myelofibrosis 1
Risk of underlying diseases,*1 high/low 101/27
Prior autologous stem cell transplant, yes/no 9/119
ransplantation procedures
Conditioning regimen
Flu  Mel  TBI 2 Gy or 4 Gy/8 Gy 112/2
Flu  BU  TBI 4 Gy/8 Gy 8/1
Others 5
GVHD prophylaxis, cyclosporine/tacrolimus 64/64
Number of infused nucleated cell, median
(range) 107/kg 2.7 (1.6-4.8)
HLA disparity (antigen), 2/1/0 108/17/3
ransplantation outcomes
Neutrophil engraftment 99/128
Complete donor chimerism*2 90/99
Grade II-IV acute GVHD*2 45/99
Chronic GVHD*3*4 11/40
CMV antigenemia*3 48/93
CMV disease 10
Relapse*2 24/98
1 We divided the risk of transplantation into two groups. The
low-risk group was as follows: acute myelogenous or lymphoid
leukemia in ﬁrst and second remission, chronic myelogenous
leukemia in chronic phase, and myelodysplastic syndrome re-
fractory anemia. The other patients were deﬁned as having
high-risk diseases.
2 Percentage was calculated based on 99 patients who achieved
primary engraftment.
3 Percentage was calculated based on the number of patients who
achieved engraftment and evaluated.
4 No patients received systemic corticosteroids for the treatment of
chronic GVHD.
ML indicates acute myelogenous leukemia; MDS, myelodysplastic
syndromes; ULN, upper limit of normal; GVHD, graft-versus-fhost disease; CMV, cytomegalovirus.yelodysplasia except refractory anemia (n  10), re-
ractory lymphoma (n  30), idiopathic myeloﬁbrosis
n  1), plasma cell leukemia in relapse (n  1), and
hronic myelomonocytic leukemia (n  1).
ransplantation Procedures and Supportive Cares
Transplantation procedures were shown in Table
, and we previously reported details of the procedures
6]. GVHD prophylaxis was either tacrolimus 0.03
g/kg or cyclosporine 3 mg/kg continuous infusion
tarting on day 1. Trough blood levels of these
rugs were monitored 2-3 times a week and the dos-
ge were modiﬁed to maintain the target level of
0-15 ng/mL for tacrolimus and 200-400 ng/mL for
yclosporine [10-12]. Immunosuppressants were ta-
ered off from day 100 until day 150. If grade II-IV
cute GVHD (aGVHD) developed, 1-2 mg/kg/day of
ethylprednisolone was added to cyclosporine or ta-
rolimus, and tapered from the beginning of clinical
esponse.
The diagnosis and management of preengraft-
ent immune reactions were reported previously [13].
anagement of Infections
Patients were managed in reverse isolation laminar
irﬂow-equipped rooms. All patients received tosu-
oxacin 450 mg/day from the start of conditioning
ntil neutrophil engraftment. Fluconazole 200 mg/
ay or micafungin 150 mg/day, and acyclovir 600
g/day were given from the start of conditioning until
he discontinuation of GVHD prophylaxis, which
ere restarted when patients developed GVHD and
ere treated with steroids and immunosuppressants.
hey received prophylaxis with trimethoprim-sulfa-
ethoxazole against Pneumocystis jirovecii infection
rom the start of conditioning until the discontinua-
ion of immunosuppressants or disappearance of
hronic GVHD (cGVHD). When patients develop
eutropenic fever, tosuﬂoxacin was changed to broad-
pectrum antibiotics [14]. Intravenous administration
f amphotericin B at a dose of 0.5 mg/kg/day was
dded when the fever persisted for more than 5 to 7
ays. If the diagnosis of aspergillus infection was con-
rmed, the dosage of amphotericin B was increased to
.0 mg/kg/day. We used blood tests, enzyme-linked
mmunosorbent assay for galactomannan antigen, (1-
)-beta-D glucan assay, and chest computed tomog-
aphy for the early diagnosis of invasive aspergillosis
IA), as previously reported [15]. Because most pa-
ients had been heavily treated and received multiple
ransfusions prior to transplantation, anti-CMV anti-
odies were not examined before transplantation. All
atients were monitored for cytomegalovirus pp65
ntigenemia once a week. When CMV antigenemia
xceeded 10/50,000, patients preemptively received
oscarnet 30 mg/kg intravenously twice daily.
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IFI after RICBT 773iagnostic Criteria for IFI
Invasive fungal infection was diagnosed according
o the established EORTC/NIH-MSG criteria [16].
rieﬂy, we diagnosed patients as having proved IFI
hen any 1 of the following examinations was posi-
ive: histopathologic or cytopathologic examinations
or hyphae or yeasts in needle aspiration or biopsy
pecimens, fungal cultures obtained from normally
terile sites by sterile procedures, and Cryptococcus an-
igen in cerebrospinal ﬂuid. Probable IFI was diag-
osed when a patient satisﬁed at least 1 host factor,
icrobiologic criteria, and clinical criteria. Possible
FI was not included in this study. The day of diag-
osis of IFI was deﬁned as the day when the ﬁrst
iagnostic test was performed.
ndpoints and Statistical Analysis
The cumulative incidence of IA was evaluated us-
ng Gray’s method, considering death without IA as a
ompeting risk [17].
Potential confounding factors considered in the
nalysis of risk factors of IA were age, sex, disease
tatus, previous stem cell transplantation, condition-
ng regimens, HLA mismatch, stem-cell dose (all
ucleated cells, and CD 34-positive cells), GVHD
rophylaxis, grade II-IV aGVHD, and use of pred-
isolone. Proportional hazard modeling was used to
valuate the inﬂuence of these factors on the inci-
ences of IA treating the development of aGVHD and
he use of prednisolone as time-dependent covariates.
actors associated with at least borderline signiﬁcance
P  .10) in the univariate analyses were subjected to
multivariate analysis using backward stepwise pro-
ortional-hazard modeling. P-values of .05 were
onsidered statistically signiﬁcant. Survival was esti-
ated by the Kaplan-Meier method. Median fol-
ow-up of surviving patients was 628 days (range:
6-1347 days).
ESULTS
linical Outcomes after RICBT
Ninety-nine (77%) patients achieved primary en-
raftment at a median of day 20 (range: 9-53 days). Of
he remaining 29 patients who failed to achieve pri-
ary engraftment, 4 patients received second RICBT,
nd the other 25 patients died before engraftment.
heir causes of death included bacteremia (n  22),
nvasive pulmonary aspergillosis (IPA) (n  1), and
rogression of primary disease (n  2). Of the 99
ngrafted patients, 45 and 22 patients developed grade
I and grade III-IV aGVHD, respectively. The me-
ian onset of grade II-IV aGVHD was day 28 (range,
1-92). Eleven of 40 patients (28%) who survived
onger than 100 days without disease progression de- meloped cGVHD. Estimated 3-year overall survival
as 33% (95% conﬁdence interval (95% CI), 24%-
2%). Causes of deaths comprised nonrelapse mortal-
ty (n  31) and disease progression (n  23). Infec-
ion was the leading cause of nonrelapse mortality (n
20). Autopsy was performed in 5 patients (3.9%) in
his series of patients.
ncidence and Clinical Features of IFI
Invasive fungal infection was diagnosed in 14 pa-
ients. Their clinical features are shown in Table 2.
hirteen of the 14 patients had probable IA, and the
ther had fungemia from Trichosporon spp. Three-year
umulative incidence of probable IA was 10.2% (Fig-
re 1). Median onset of IFI was day 20 (range: 1-82),
nd no patients developed IFI after day 100. IFI was
iagnosed after day 30 in 1 patient. Prophylactic uses
f antifungal agents included ﬂuconazole (n 12) and
icafungin (n  1) among the 13 patients with IA. Of
he 63 patients who survived 100 days or longer, none
eveloped IFI after day 100. Four of the 13 patients
ith IFI developed grade II-IV aGVHD, and their
iagnosis of IFI was before the onset of aGVHD
Table 2).
Seven patients were given prednisolone 0.2 mg/
g/day for the treatment of preengraftment immune
eactions, of whom 5 developed grade II-IV aGVHD.
welve of the 14 patients with IFI died, and the
ortality rate was 86%. IFI was the primary cause of
eaths in 4 patients.
isk Factors of IPA
Table 3 shows the results of univariate and mul-
ivariate analyses. Reactivation of cytomegalovirus
CMV) is a well-known risk factor of IA [18,19]. How-
ver, it was not included in the analysis of this study,
ecause the onset of IFI was earlier than the onset of
MV antigenemia. Use of prednisolone 0.2 mg/kg
relative risk [RR], 7.97; 95% CI, 2.24-28.4; P 
0014) was a signiﬁcant risk factor in multivariate
nalysis.
ISCUSSION
The present study demonstrated that IFI early
fter RICBT is a signiﬁcant complication. Among IFI,
he incidence of IA was high, which was consistent
ith the studies on reduced intensity stem cell trans-
lantation (RIST) using other stem cell sources [9,19].
ur results contrasted with the previous reports that
he incidence of infection because of non-Candidia
lbicans species was high in myeloablative allogeneic
tem cell transplantation [20]. The observations may
e associated with the milder gastrointestinal mucosal
oxicity by conditioning regimens in RIST than in
yeloablative transplantation [21] and the less fre-
Table 2. Clinical Characteristics of Patients with Invasive Aspergillosis
UPN Age Sex
Primary
Disease
Disease
Status at
Transplant
No. of
Prior
Regimens
Neutrophil
Engraftment
Day
Grade II-IV
Acute GVHD
Onset Day
PSL
Started
Invasive Fungal
Infection
(IFI)*1
Onset
(Day)
Other
Infectious
Complication
Overall
Survival
(Day)
Outcomes
of IFI
Causes
of Death
286 57 M AML PIF 3 Probable IA 4 4 dead IFI
365 69 M AML RL1 3 Probable IA 3 14 dead IFI
411 56 F ML PD 1 11 Probable IA 19 Bacteremia 24 dead Bacteremia
complicated with IA
196 61 M AML PIF 2 11 22 T. cutaneum
fungemia
1 28 dead IFI
202 62 M AML RL1 4 21 21 8 Probable IA 21 Bacteremia 28 dead Bacteremia
complicated with IA
344 55 F ML PD 1 19 Probable IA 4 Bacteremia 30 dead IFI
262 59 M AML PIF 1 10 Probable IA 20 31 dead PD
151 52 F MDS RAEB 3 20 7 Probable IA 12 33 improved GI bleeding
114 52 F ML PD 4 13 0 Probable IA 23 39 dead PD
153 70 M AML 1st CR 2 14 30 Probable IA 29 Bacteremia 46 dead IP
197 33 M MDS RA 0 Probable IA 28 Bacteremia 47 dead Bacteremia
complicated with IA
160 66 M ML PD 2 14 29 9 Probable IA 25 75 dead MOF
120 70 F SAA 0 13 Probable IA 82 1308 improved
127 20 M SAA 3 31 55 12 Probable IA 3 1347 improved
AML indicates acute myelogenous leukemia; MDS, myelodysplastic syndromes; CR, complete remission; GI, gastrointestinal; IA, invasive aspergillosis; IFI, invasive fungal infection; SAA, severe aplastic
anemia; RA, refractory anemia; PD, progressive disease; PIF, primary induction failure; RARB, refractory anemia with excess of blasts; MOF, multiple organ failure.
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IFI after RICBT 775uent and milder GVHD following CBT. Because
astrointestinal mucosal toxicity is milder in RICBT
han in myeloablative transplantation, the incidence of
nfection from non-Candida albicans species as part of
he gastrointestinal normal ﬂora might be low, and
ence aspergillus infection might become the majority
f IFI.
The median onset of IFI was day 20 (range: 1-82)
n the present study; the majority developed IFI early
fter RICBT. Majority of the patients who developed
FI died of causes other than fungal infection (Table
), as reported previously by Saavedra et al. [7]. Our
esults were consistent with a previous report on CBT
18], and contrasted to reports on RIST using marrow
r peripheral blood [19,22,23], in which IA develops
ate after transplantation. The low incidence of IA
fter day 100 would be related to the low incidence of
GVHD. The short duration from RICBT to IFI
evelopment suggests aggravation of latent infection,
hich would have existed before transplantation.
hese ﬁndings were consistent with a recent report by
artino et al. [23]. Given the possibility, several issues
eed to be addressed in the management of IFI fol-
owing RICBT. First, selection of RICBT candidates
ould have to include accurate evaluation for the risk
f fungal infection [24] and high-risk patients might
eed to be excluded from the indication of RICBT.
retransplant CT scan of the chest and sinus would be
seful in the screening of IA following RICBT, and
ronchoalveolar lavage should be performed in pa-
ients with abnormal ﬁndings. Second, the importance
eeds to be stressed in prophylactic antifungal agents
ith antiaspergillus activity and attempts for early
iagnosis of aspergillosis such as methods using mo-
ecular techniques [25], antigen tests [26], and imaging
ests [15,22]. Third, the way of steroid use after
ICBT requires further investigations. The present
tudy showed that the administration of steroids 0.2
igure 1. Cumulative incidence of invasive aspergillosis (IA) con-
idering death without IA as a competing risk. Black line indicates
ncidence of death with IA, and gray line indicates incidence of
eath without IA.g/kg and more was a strong risk factor of IA (RR,.97; 95% CI, 2.24-28.4; p  .0014). Our observation
hat the use of small-dose steroids was a risk factor of
FI after RICBT supports the previous results of se-
ere immunosuppression early after RICBT [27]. In
ICBT using our regimens, immunologic reactions
uch as a preengraftment immune reaction frequently
evelops in addition to GVHD, requiring steroid ad-
inistration early after RICBT [13]. Because steroids
uppress phagocyte activities and cellular immunity
28], the risk of fungal infection early after RICBT
ay be increased.
The incidence of late IFI was not high in the
resent study. Of 102 patients who survived longer
able 3. Univariate and Multivariate Analyses for the Incidence of IA
Incidence of IPA
(95% CI)
P
Value
nivariate analysis
Pretransplantation factors
Age .30
<55 7%
>55 13%
Sex .94
Female 11%
Male 10%
Disease risk .63
Standard 16%
High 9%
Previous ASCT .55
No 11%
Yes 0%
Regimen .72
FM-based 11%
FB-based 10%
HLA mismatch .076
0 or 1 antigen 0%
2 antigens 12%
Cell dose .42
ANC <2.5  107/kg 8%
ANC >2.5  107/kg 12%
Cell dose .03
CD34 <0.8  106/kg 5%
CD34 >0.8  106/kg 16%
GVHD prophylaxis .42
Cyclosporine 13%
Tacrolimus 8%
Fungal prophylaxis .99
Fluconazole 10%
Micafungin 10%
Posttransplantation factors
(time-dependent covariates)
Acute GVHD .96
Grade 0-I 1.00
Grade II-IV 1.06 (0.12-9.40)
Prednisolone .001
<0.2 mg/kg/day 1.00
>0.2 mg/kg/day 7.97 (2.24-28.4)
ultivariate analysis
Prednisolone .0014
<0.2 mg/kg/day 1.00
>0.2 mg/kg/day 7.97 (2.24-28.4)
VHD indicates graft-versus-host disease; ASCT, autologous stem
cell transplantation.
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S. Miyakoshi et al.776han 30 days, 1 patients developed IFI after day 30.
one of 63 patients who survived longer than 100
ays developed IFI after day 100. Our results contrast
ith the previous reports on BMT and PBSC trans-
lantation where improvement in fungal management
ecreased early IFI and late IFI became the majority
f IFI [8,19,22,29]. In myeloablative CBT, late infec-
ion is considered a signiﬁcant complication [4],
hereas study results focused on fungal infection have
ot been published. Some hypotheses can explain the
ow incidence of late IFI after RICBT. First, cGVHD
fter RICBT is uncommon and mild. There is mini-
al effect of cGVHD on delay in immune recovery
ollowing RICBT. Second, steroids are not frequently
dministered late after RICBT for the treatment of
omplications such as GVHD. The incidence of
GVHD was 28% in the present study, and none of
hem required steroid treatments. Further studies are
waited for the clinical features of late IFI after
ICBT.
The present study demonstrated clinical features
f fungal infections after RICBT, leaving several is-
ues to be investigated. First, the present study is a
mall-sized retrospective 1 . Unrecognized bias might
ffect the study results, and we obtained little infor-
ation on rare fungal infections such as Fusarium and
ygomycetes. Large-sized prospective studies are
waited. Second, the diagnostic yields of IFI need to
e addressed. Most of the diagnoses in our study were
ade based on EORTC/MSG criteria [16] using clin-
cal, laboratory, and imaging ﬁndings. Although the
linical usefulness of the diagnostic criteria has been
stablished, pathologic diagnosis of IFI was not con-
rmed in many patients and the diagnostic yields
emain unclear. Underestimation of IFI incidence also
emains possible, because postmortem examinations
ere not obtained in most patients who died without
iagnosis of IFI. Because such limitations cannot be
voided in studying deep fungal infections [30], clini-
ians need to be aware of the limitations.
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